---
title: "RDCM: Revenue declined sharply on deployment delays, but guidance and demand remain strong"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295646788.md"
description: "Q2 2026 revenue fell 33% year-over-year due to deployment delays, but demand remains strong and three new contracts were secured post-quarter. Full-year guidance is unchanged, with profitability expected on a non-GAAP basis and a share repurchase program underway.Original document: Radcom Ltd. [RDCM] SEC 6-K Current Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T10:07:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295646788.md)
  - [en](https://longbridge.com/en/news/295646788.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295646788.md)
generator: "portal-rs"
---

# RDCM: Revenue declined sharply on deployment delays, but guidance and demand remain strong

Q2 2026 revenue fell 33% year-over-year due to deployment delays, but demand remains strong and three new contracts were secured post-quarter. Full-year guidance is unchanged, with profitability expected on a non-GAAP basis and a share repurchase program underway.

Original document: Radcom Ltd. \[RDCM\] SEC 6-K Current Report — Aug. 12 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RDCM.US](https://longbridge.com/en/quote/RDCM.US.md)

## Related News & Research

- [VNPT selects Radcom to provide cloud-based service assurance for roaming network](https://longbridge.com/en/news/298444990.md)
- [RDCM: Q2 revenue dropped 33% year-over-year, but strong pipeline and share buyback signal confidence](https://longbridge.com/en/news/295677715.md)
- [UNFI: Guidance for renewed growth in H2 2027 is backed by operational gains and a focused market strategy](https://longbridge.com/en/news/299055727.md)
- [BBIO: Attruby's clinical edge and new launches drive growth, targeting profitability by 2027](https://longbridge.com/en/news/299073915.md)
- [Is Oklo the next great AI power story? Here's the bull case.](https://longbridge.com/en/news/298658428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**